0.37
+0.075(+25.51%)
Currency In USD
| Previous Close | 0.29 |
| Open | 0.32 |
| Day High | 0.39 |
| Day Low | 0.31 |
| 52-Week High | 2.63 |
| 52-Week Low | 0.22 |
| Volume | 2.63M |
| Average Volume | 799,266 |
| Market Cap | 18.96M |
| PE | -0.04 |
| EPS | -8.31 |
| Moving Average 50 Days | 0.63 |
| Moving Average 200 Days | 1.51 |
| Change | 0.08 |
If you invested $1000 in Eterna Therapeutics Inc. (ERNA) 10 years ago, it would be worth $0.42 as of January 03, 2025 at a share price of $0.369. Whereas If you bought $1000 worth of Eterna Therapeutics Inc. (ERNA) shares 5 years ago, it would be worth $4.27 as of January 03, 2025 at a share price of $0.369.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
GlobeNewswire Inc.
Dec 03, 2024 1:30 PM GMT
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA) today announced it will investigate the ability of its lead iMSC-based cell therapy (ERNA-101) to induce and modulate antitumor immunity in ovarian cancer and br
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
GlobeNewswire Inc.
Nov 25, 2024 1:30 PM GMT
CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (Nasdaq: ERNA), a leader in cell therapies, today announced that its Board of Directors has authorized a stock repurchase program of up to $1 million of the company’s out
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
GlobeNewswire Inc.
Nov 14, 2024 1:30 PM GMT
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on T